Page 97 - TD-3-4

Tumor Discovery RNA-protein complexes deregulated in cancer

doi: 10.1053/j.gastro.2020.08.018 doi: 10.1038/s41598-022-17829-1
257. Sha S, Yuan D, Liu Y, Han B, Zhong N. Targeting long 268. Lemos C, Schulze L, Weiske J, et al. Identification of small
noncoding RNA DANCR inhibits triple-negative breast molecules that modulate mutant p53 condensation. iScience.
cancer progression. Biol Open. 2017;6(9):1310-1316. 2020;23(9):101517.
doi: 10.1242/bio.023135 doi: 10.1016/j.isci.2020.101517
258. Ehmann F, Kuhn A, Pasmooij AMG, et al. Report of the 269. Donlic A, Zafferani M, Padroni G, et al. Regulation of the
European medicines agency conference on RNA-based MALAT1 triple helix stability and in vitro degradation by
medicines. Nucleic Acid Ther. 2024;34:4-11. diphenylfuran. Nucleic Acids Res. 2020;48:7653-7664.
doi: 10.1089/nat.2023.0021 doi: 10.1093/nar/gkaa585
259. Benhamou RI, Suresh BM, Tong Y, et al. DNA-encoded 270. Meyer SM, Tanaka T, Taghavi A, Baisden JT, Grefe M,
library versus RNA-encoded library selection enables design Disney MD. Optimization of a protein-targeted medicine
of an oncogenic noncoding RNA inhibitor. Proc Natl Acad into an RNA-specific small molecule. ACS Chem Biol.
Sci U S A. 2022;119:e2114971119. 2023;18(11):2336-2342.
doi: 10.1073/pnas.2114971119 doi: 10.1021/acschembio.3c00476
260. Bouchard JJ, Otero JH, Scott DC, et al. Cancer mutations 271. False JP, Donlic A, Hargrove AE. Targeting RNA with small
in the tumor suppressor SPOP disrupt the formation molecules: From fundamental principles toward the clinic.
of active, phase-separated compartments. Mol Cell. Chem Soc Rev. 2021;50(4):2224-2243.
2018;72(1):19-36.e8.
doi: 10.1039/d0cs01261k
doi: 10.1016/j.molcel.2018.08.027
272. Xiao H, Yang X, Zhang Y, Zhang Z, Zhang G, Zhang BT.
261. Grabocka E, Bar-Sagi D. Mutant KRAS enhances RNA-targeted small-molecule drug discoveries: a machine-
tumor cell fitness by upregulating stress granules. Cell. learning perspective. RNA Biol. 2023;20(1):384-397.
2016;167(7):1803-1813.e12.
doi: 10.1080/15476286.2023.2223498
doi: 10.1016/j.cell.2016.11.035
273. Kim T, Kim TK. Regulatory RNA: From molecular insights to
262. Zhang J, Zeng Y, Xing Y, et al. Myristoylation-mediated therapeutic frontiers. Exp Mol Med. 2024;56(6):1233-1234.
phase separation of EZH2 compartmentalizes STAT3 to
promote lung cancer growth. Cancer Lett. 2021;516:84-98. doi: 10.1038/s12276-024-01267-2
doi: 10.1016/j.canlet.2021.05.035 274. Li K, Wang H, Jiang B, Jin X. TRIM28 in cancer and cancer
therapy. Front Genet. 2024;15:1431564.
263. Xu WX, Qu Q, Zhuang HH, et al. The burgeoning significance
of liquid-liquid phase separation in the pathogenesis and doi: 10.3389/fgene.2024.1431564
therapeutics of cancers. Int J Biol Sci. 2024;20(5):1652-1668. 275. Zhu Y, Li J, Li S, et al. ZMAT2 condensates regulate the
doi: 10.7150/ijbs.92988 alternative splicing of TRIM28 to reduce cellular ROS
accumulation, thereby promoting the proliferation of HCC
264. Li J, Zhang Y, Gu J, et al. Stress granule core protein-derived cells. Cell Commun Signal. 2024;22(1):407.
peptides inhibit assembly of stress granules and improve
sorafenib sensitivity in cancer cells. Molecules (Basel). doi: 10.1186/s12964-024-01790-9
2024;29(9):2134. 276. Christen KE, Davis RA, Kennedy D. Psammaplysin F
doi: 10.3390/molecules29092134 increases the efficacy of bortezomib and sorafenib through
the regulation of stress granule formation. Int J Biochem Cell
265. Bechara C, Sagan S. Cell-penetrating peptides: 20 years later, Biol. 2019;112:24-38.
where do we stand? FEBS Lett. 2013;587:1693-1702.
doi: 10.1016/j.biocel.2019.04.008
doi: 10.1016/j.febslet.2013.04.031
277. Mitrea DM, Mittasch M, Ferreira Gomes B, Klein IA,
266. Chen Y, Lan T. N-terminal domain of androgen receptor is Murcko MA. Modulation of biomolecular condensates:
a major therapeutic barrier and potential pharmacological A novel approach to drug discovery. Nat Rev Drug Discov.
target for treating castration resistant prostate cancer: 2022;21(11):841-862.
A comprehensive review. Front Pharmacol. 2024;15:1451957.
doi: 10.1038/s41573-022-00505-4
doi: 10.3389/fphar.2024.1451957
278. Wheeler RJ, Lee OH, Poser I, et al. Small Molecules for
267. Kamagata K, Ariefai M, Takahashi H, et al. Rational peptide
design for regulating the liquid-liquid phase separation Modulating Protein Driven Liquid‑Liquid Phase Separation
on the basis of the residue-residue contact energy. Sci in Treating Neurodegenerative Disease. BioRixv preprint.
Rep. 2022;12(1):13718. doi: 10.1101/721001

Volume 3 Issue 4 (2024) 38 doi: 10.36922/td.4657